Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18658896 | CEACAM5-DEPENDENT 4-1BB-AGONISTIC BISPECIFIC ANTIBODIES | May 2024 | November 2024 | Allow | 6 | 1 | 0 | No | No |
| 18623883 | NUCLEASES AND COMPOSITIONS, SYSTEMS, AND METHODS THEREOF | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18490445 | MAJOR HISTOCOMPATIBILITY COMPLEX-BASED CHIMERIC RECEPTORS AND USES THEREOF FOR TREATING AUTOIMMUNE DISEASES | October 2023 | May 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18365828 | HER2 TARGETING AGENT | August 2023 | March 2024 | Allow | 7 | 1 | 0 | No | No |
| 18153993 | ANTIBODY SPECIFIC TO NECTIN CELL ADHESION MOLECULE 4 AND USES THEREOF | January 2023 | December 2024 | Allow | 23 | 0 | 1 | Yes | No |
| 18054043 | BASELINE SERUM AUTOANTIBODIES FOR PREDICTING RECURRENCE AND TOXICITY FOR IMMUNE CHECKPOINT BLOCKADE IN CANCER PATIENTS | November 2022 | May 2025 | Abandon | 30 | 2 | 1 | No | Yes |
| 17821295 | ANTI-CD-25 ANTIBODY | August 2022 | June 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17872131 | APPLICATION OF SCFV PROTEIN, CAR GENE EXPRESSION VECTOR, CAR-T CELL AND APPLICATION THEREOF | July 2022 | April 2024 | Allow | 21 | 1 | 0 | No | No |
| 17684211 | COMBINATION OF CTLA4 AND PD1/PDL1 ANTIBODIES FOR TREATING CANCER | March 2022 | August 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17555616 | NUCLEIC ACIDS ENCODING ANCHOR MODIFIED ANTIBODIES AND USES THEREOF | December 2021 | March 2025 | Allow | 39 | 2 | 2 | Yes | No |
| 17506370 | Compositions and Methods for Preventing the Interaction Between SARS-COV-2 and L-Sign | October 2021 | May 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17602880 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER | October 2021 | June 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17430311 | FCMR-Binding Molecules and Uses Thereof | August 2021 | December 2024 | Allow | 40 | 1 | 1 | No | No |
| 17429106 | ASPERGILLUS ANTIGEN CHIMERIC RECEPTORS AND USE THEREOF | August 2021 | January 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17310204 | ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF | July 2021 | March 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17422609 | HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE | July 2021 | June 2024 | Allow | 35 | 0 | 0 | Yes | No |
| 17369989 | ANTIBODIES FOR TREATING MALIGNANT TUMORS AND USES THEREOF | July 2021 | June 2025 | Allow | 48 | 2 | 0 | No | No |
| 17420348 | BACTERIA-DERIVED VESICLES AND USES THEREOF | July 2021 | January 2025 | Allow | 43 | 1 | 0 | No | No |
| 17365881 | THERAPEUTIC PEPTIDES AND METHODS FOR TREATING TYPE 2 DIABETES | July 2021 | June 2025 | Allow | 47 | 4 | 1 | Yes | No |
| 17418856 | BIVALENT BISPECIFIC ANTIBODY AND PREPARTION METHOD THEREOF, CODING GENE, HOST CELL AND COMPOSITION | June 2021 | June 2025 | Allow | 47 | 1 | 1 | No | No |
| 17414471 | CD22-SPECIFIC T CELL RECEPTORS AND ADOPTIVE T CELL THERAPY FOR TREATMENT OF B CELL MALIGNANCIES | June 2021 | June 2025 | Allow | 48 | 1 | 1 | No | No |
| 17346156 | LOW-VISCOSITY ANTIGEN BINDING PROTEINS AND METHODS OF MAKING THEM | June 2021 | January 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17298741 | ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF | June 2021 | September 2024 | Allow | 39 | 0 | 1 | No | No |
| 17297967 | THERAPEUTIC FACTOR XII ANTIBODY | May 2021 | July 2024 | Allow | 38 | 1 | 0 | No | No |
| 17244856 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | April 2021 | December 2024 | Allow | 44 | 1 | 0 | No | No |
| 17288641 | DOSING REGIMEN OF ANTI-TIGIT ANTIBODY FOR TREATMENT OF CANCER | April 2021 | June 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17288894 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH FAMITINIB IN PREPARATION OF DRUG FOR TREATING TUMORS | April 2021 | October 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17284192 | ANTIBODY COMPOUNDS WITH REACTIVE ARGININE AND RELATED ANTIBODY DRUG CONJUGATES | April 2021 | December 2024 | Allow | 45 | 1 | 0 | Yes | No |
| 17191722 | DEVELOPMENT OF RECOMBINANT CHICKEN IGY SCFV ANTIBODY RAISED AGAINST HUMAN THYMIDINE KINASE 1 EXPRESSED IN PROKARYOTIC CELLS AND USE THEREOF | March 2021 | July 2024 | Allow | 40 | 1 | 0 | No | No |
| 17272083 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF | February 2021 | November 2024 | Allow | 44 | 1 | 1 | No | No |
| 17169091 | IFN-GAMMA-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF | February 2021 | August 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17153165 | METHODS AND COMPOSITIONS FOR TREATING PAIN | January 2021 | October 2024 | Allow | 45 | 3 | 0 | Yes | No |
| 17260077 | ANTI-GALECTIN-9 ANTIBODY AND METHODS OF USE THEREOF | January 2021 | November 2023 | Allow | 34 | 0 | 0 | Yes | No |
| 17254006 | ANTIBODY INDUCING IMMUNE TOLERANCE, INDUCED LYMPHOCYTE, AND CELL THERAPY AGENT THERAPEUTIC METHOD USING INDUCED LYMPHOCYTE | December 2020 | July 2024 | Allow | 43 | 1 | 1 | No | No |
| 17117647 | Method of treating type 2 diabetic patient with FPP | December 2020 | October 2022 | Allow | 22 | 6 | 1 | Yes | Yes |
| 17042374 | ANTIBODY BINDING SPECIFICALLY TO ECL-2 OF CLAUDIN 3, FRAGMENT THEREOF, AND USE THEREOF | September 2020 | March 2024 | Allow | 42 | 0 | 1 | Yes | No |
| 17024158 | HER-1, HER-3 AND IGF-1R COMPOSITIONS AND USES THEREOF | September 2020 | August 2024 | Abandon | 47 | 1 | 1 | No | No |
| 16971098 | ANTIBODY VARIABLE DOMAINS TARGETING CD33, AND USE THEREOF | August 2020 | February 2025 | Allow | 54 | 1 | 1 | Yes | No |
| 16961942 | TREATMENT AND PREVENTION OF SEED ALLERGIES | July 2020 | December 2024 | Allow | 53 | 2 | 1 | No | No |
| 16926771 | APHERESIS TO REMOVE INTERFERING SUBSTANCES | July 2020 | February 2024 | Abandon | 43 | 1 | 0 | No | No |
| 16921969 | ANTI-TUMOR DRUG COMPOSITION AND POLYNUCLEOTIDE COMPOSITION | July 2020 | January 2025 | Abandon | 55 | 3 | 0 | No | No |
| 16464651 | FAB-LINKED GLYCANS AS BIOMARKER FOR THE TRANSITION FROM A PRE-DISEASE "AT-RISK-PHASE" TO RHEUMATOID ARTHRITIS; AAV OR SJ�GREN SYNDROME | May 2019 | July 2024 | Allow | 60 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DRISCOLL, MAUREEN VARINA.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner DRISCOLL, MAUREEN VARINA works in Art Unit 1644 and has examined 40 patent applications in our dataset. With an allowance rate of 77.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 43 months.
Examiner DRISCOLL, MAUREEN VARINA's allowance rate of 77.5% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by DRISCOLL, MAUREEN VARINA receive 1.48 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by DRISCOLL, MAUREEN VARINA is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +39.1% benefit to allowance rate for applications examined by DRISCOLL, MAUREEN VARINA. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 31.8% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 11% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 57.1% are granted (fully or in part). This grant rate is in the 72% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 12.9% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.